ClinicalTrials.gg
CompletedNCT05633862Updated Nov 28, 2025Results posted

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

A Phase 1 interventional study of BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Chinese subjects will only be included in the trial if they meet the following criteria:

  1. Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  2. Age of 18 to 55 years (inclusive)
  3. (BMI) of 18.5 to 28.0 kg/m² (inclusive)
  4. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial
  5. Women of (WOCBP) must be ready and able to use highly effective methods of . Of note, oral hormonal contraceptives are not considered a highly effective method due to potential drug-drug interactions. A list of contraception methods meeting these criteria and instructions on the duration of their use is provided in the patient information.

Exclusion criteria

Exclusion criteria

Subjects will not be allowed to participate, if any of the following general criteria apply:

  1. Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimeter of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders (including but not limited to major depressive disorder or any history of suicidal ideation or behaviour)
  8. History of relevant orthostatic hypotension, fainting spells, or blackouts. Further exclusion criteria apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    BI 1015550 9 mg

    A single film-coated tablet of 9 milligram BI 1015550 taken orally after an overnight fast of at least 10 hours.

    Drug: BI 1015550

  • Experimental
    BI 1015550 18 mg

    A single film-coated tablet of 18 milligram BI 1015550 taken orally after an overnight fast of at least 10 hours.

    Drug: BI 1015550

Interventions

  • A single film-coated tablet BI 1015550 taken orally after an overnight fast of at least 10 hours.

    Also known as: Nerandomilast, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).

    Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours following drug administration.

  2. Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)

    Maximum measured concentration of BI 1015550 in plasma (Cmax).

    Time frame: Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours following drug administration.

Secondary outcomes

  1. Number of Subjects With Any Treatment-emergent Adverse Event (AE)

    Number of subjects with any treatment-emergent adverse event (AE).

    Time frame: Up to 7 days.

07

Results

Posted Nov 28, 2025

Participant flow

This was a non-randomised, uncontrolled, open label, single-dose, parallel-group design trial.

Participant flow — Overall Study
MilestoneBI 1015550 9 mgBI 1015550 18 mg
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).

Time frame:
Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours following drug administration.
Reported as:
Geometric mean · Nanomol*Hour/Liter
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Nanomol*Hour/LiterBI 1015550 9 mgBI 1015550 18 mg
Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)1780 ± 19.13680 ± 32.6
PrimaryMaximum Measured Concentration of BI 1015550 in Plasma (Cmax)

Maximum measured concentration of BI 1015550 in plasma (Cmax).

Time frame:
Within 3 hours before and 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hours following drug administration.
Reported as:
Geometric mean · Nanomol/Liter
Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)
Nanomol/LiterBI 1015550 9 mgBI 1015550 18 mg
Maximum Measured Concentration of BI 1015550 in Plasma (Cmax)325 ± 30.3591 ± 39.0
SecondaryNumber of Subjects With Any Treatment-emergent Adverse Event (AE)

Number of subjects with any treatment-emergent adverse event (AE).

Time frame:
Up to 7 days.
Reported as:
Count of participants · Participants
Number of Subjects With Any Treatment-emergent Adverse Event (AE)
ParticipantsBI 1015550 9 mgBI 1015550 18 mg
Number of Subjects With Any Treatment-emergent Adverse Event (AE)26

Adverse events

Collected over Adverse events: Up to 7 days. All-cause mortality: Up to 14 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 1015550 9 mg0/12 (0%)0/12 (0%)2/12 (16.7%)
BI 1015550 18 mg0/12 (0%)0/12 (0%)6/12 (50%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventBI 1015550 9 mgBI 1015550 18 mg
Alanine aminotransferase increasedInvestigations0/122/12
White blood cells urine positiveInvestigations0/122/12
Aspartate aminotransferase increasedInvestigations0/121/12
Basophil count increasedInvestigations0/121/12
C-reactive protein increasedInvestigations1/120/12
Eosinophil count increasedInvestigations0/121/12
Gamma-glutamyltransferase increasedInvestigations0/121/12
Neutrophil count increasedInvestigations0/121/12
Urinary occult blood positiveInvestigations1/120/12
White blood cell count increasedInvestigations0/121/12

Baseline characteristics

Treated set (TS): The treated set included all subjects who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(years)BI 1015550 9 mgBI 1015550 18 mgTotal
Mean36.7 ± 4.929.8 ± 1.933.3 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)BI 1015550 9 mgBI 1015550 18 mgTotal
Female6511
Male6713
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BI 1015550 9 mgBI 1015550 18 mgTotal
Hispanic or Latino000
Not Hispanic or Latino121224
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BI 1015550 9 mgBI 1015550 18 mgTotal
Asian Indian000
Chinese121224
Japanese000
Korean000
Other Asian000
Southeast Asian000
Taiwanese000
08

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, 100032, China
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Mar 2023, 2 months.

Results were first posted in Nov 2025, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Dec 1, 2022
StartActual
Jan 13, 2023
Primary completionActual
Mar 16, 2023
CompletionActual
Mar 17, 2023
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05633862
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Jan 13, 2023
Primary completion
Mar 16, 2023
Completion
Mar 17, 2023
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion